Gefitinib may be effective to treat esophageal cancer in some patients
the ONA take:
According to new research published in The Lancet Oncology, gefitinib, a drug already used to treat lung cancer, may be effective to treat esophageal cancer in a small subgroup of patients. In the Cancer Oesophagus Gefitinib study, researchers tested gefitinib in patients with esophageal cancer who had progressed after chemotherapy.
The study showed that gefitinib had minimal impact on most patients and only increased survival rates by a small amount; however, the drug did drastically improve the quality of life, survival duration, and symptom control in about 15% of patients. The main adverse effect was diarrhea.
Russell Petty, PhD, of the University of Aberdeen in Aberdeen, Scotland and senior researcher of the study said that the patients who improved on gefitinib did so within a few weeks of initiating therapy and some patients had disease control for almost 2 years. Dr. Petty notes that not all patients with esophageal cancer should be offered gefitinib and that there is a need for a test to screen whether a patient would improve on gefitinib.
Gefitinib (Iressa), a tyrosine kinase inhibitor, was approved in 2003 by the U.S. Food and Drug Administration to treat advanced EGFR mutation-positive non-small cell lung cancer.
Findings of a trial could lead to a new treatment approach for oesophageal cancer.
The University of Aberdeen was involved in a UK wide study to see if the drug gefitinib - already used in lung cancer - could help treat oesophageal cancer.
The Cancer Oesophagus Gefitinib trial was the first study conducted in oesophageal cancer patients whose disease had progressed after chemotherapy.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
- Nonadherence to Posttreatment Imaging Follow-up Common Among Breast Cancer Survivors
- HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|